Clinical Trials Browser

INDUSTRY × Lymphoma, B-Cell × Bortezomib × Clear all

NCT00085696 2008-02-11

VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma

Phase 2 Completed

Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell